NEXT

Steve Schain

Steve Schain

December 09, 2022 | The Legal Intelligencer

Cannabis' Plummeting Price-Per-Pound and the Rise of Delta-8 THC

Although forming America's sixth-largest crop yielding 48.8 million pounds of flower and $27 billion in legal sales annually, marijuana's plunging price-per-pound and the availability of cheaper, unregulated hemp-derived tetrahydrocannabinol (THC) products is thwarting the cannabis industry.

By Steve Schain

10 minute read

November 04, 2022 | The Legal Intelligencer

How Cannabis Is Looking to Conquer NFTs and the Metaverse

While offering to solve cannabis' most severe woes, it is unclear whether the "shared, immersive virtual world" metaverse's reach exceeds its grasp or whether cryptographic, blockchain asset non fungible tokens are "all flash and no cash."

By Steve Schain

9 minute read

August 25, 2022 | The Legal Intelligencer

Are 'Cannabis Appellations' Malarkey? A Look at Calif.'s New Program

While aspiring to mirror its wine industry counterparts' success and empower small growers to compete in an increasingly challenging marketplace, it is unclear whether a critical mass of consumers is willing to pay a premium price for appellation-containing cannabis or what impact federal marijuana legalization will have on state-based cannabis certification.

By Steve Schain

9 minute read

June 21, 2022 | The Legal Intelligencer

The 'God Molecule'—How Bufo Is Revolutionizing Hallucinogens

Are hallucinogens' skyrocketing sales arising from a poisonous toad?

By Steve Schain

8 minute read

April 28, 2022 | The Legal Intelligencer

Valuing That Golden Ticket: What's a Marijuana License Actually Worth?

Building a cannabis enterprise requires staggering and constant fundraising and, because of the industry's dynamic nature, any given license's value is subjective, fluctuates with external factors beyond the licensee's control, and may change by the minute.

By Steve Schain

9 minute read

March 17, 2022 | The Legal Intelligencer

FDA Addresses Safety Concerns of Cannabis-Derived Products

By addressing safety, labeling, misleading claims, and adulteration concerns, DAP enables the FDA to track, authorize and regulate the sale of cannabis-derived products and accelerates CDPs entry into the interstate commerce stream.

By Steve Schain

8 minute read

December 10, 2021 | The Legal Intelligencer

Why the SAFE Banking Act Stinks for MRBs

Despite lessening criminal/administrative penalties and depository insurance obstacles, the SAFE Banking Act fails to put legal cannabis on equal footing with all other legitimate industries or make depository accounts and merchant services either available or affordable.

By Steve Schain

10 minute read

August 26, 2021 | The Legal Intelligencer

Obtaining IP Protection for Cannabis Consumer Packaged Goods

How do you protect intellectual property rights in an insanely lucrative, nearly legal ingredient poised to detonate the consumer packaged goods (CPGs) industry?

By Steve Schain

8 minute read

June 23, 2021 | The Legal Intelligencer

How Delta-8 Hemp Sucker Punched Legalized Marijuana

Mirroring legalized marijuana's tetrahydrocannabinol (Delta-9 THC) effects, hemp derived tetrahydrocannabinol (Delta-8 THC) requires no license, is readily available online and over-the-counter, and is cutting into legalized cannabis' $20 billion-plus annual revenue.

By Steve Schain

7 minute read

May 03, 2021 | The Legal Intelligencer

Data-Breach Concerns Rise as NY Launches Adult-Use Cannabis Program

Becoming the 17th state to legalize adult-use cannabis, on March 31, New York enacted the Marijuana Regulation and Taxation Act (MRTA) anticipated to generate $1.2 billion in annual sales by 2023.

By Steve Schain and Rebecca L. Rakoski

9 minute read